Abstracts tagged "scleroderma and thrombin inhibitors"

Abstract Number: 791 • ACR/ARHP Annual Meeting 2018

Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients

Rick Silver¹, Ilia Atanelishvili², Tanjina Akter², Kelley Kajdasz³, Dulaney Wilson⁴, Paul J. Nietert⁵, J. Terrill Huggins⁶, Kristin B. Highland⁷ and Galina S. Bogatkevich², ¹Rheumatology, Medical University of SC, Charleston, SC, ²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁵Public Health Science, Medical University of South Carolina, Charleston, SC, ⁶Pulmonology, Medical University of South Carolina, Charleston, SC, ⁷Rheumatology.org, Cleveland Clinic, Cleveland, OH